Tempus, a cancer data technology company that is building the world’s largest cancer data repository, is adding yet another feature to its already expansive repertoire of services it offers to oncologists, patients, academic and research institutions as well as biotechnology companies. This time it is teaming up with the American Society of Clinical Oncology, Inc. (ASCO) as a means to offer support research sites who are part of the ASCO Targeted Agent and Profiling Utilization (TAPUR™) Study. The goal of the TAPUR Study, a prospective, non-randomized clinical trial, is to elucidate both the efficacy as well as safety of targeted anticancer drugs that are administered to patients who have advanced cancer and a potentially actionable genetic marker. These drugs are approved by the Food and Drug Administration (FDA). In order for patients to participate in the study, they are required to undergo tumor profiling in a laboratory such as Tempus that is both CLIA (Clinical Laboratory Improvement Amendments of 1988)-certified as well as accredited by the College of American Pathologists.
Tempus was founded in 2015 by Chicago-based entrepreneur, Eric Lefkofsky. He set out to create a data driven, precision medicine platform that will enable doctors to have access to a wide array of sequencing technologies, all with full transcriptome and tumor/normal match. Tempus’ several partnerships are a way to enhance their partners’ current offerings by providing access to the latest and most advanced sequencing and analytics technologies as well as an interactive machine learning platform that uses the generated data across Tempus’ platform. Furthermore, Tempus’ offers its partners access to its vast repository of clinical and molecular cancer patient data that is critical in designing targeted therapies.
Already, more than 1,700 patients have provided their consent to be part of the study, while more than 1,200 have already received TAPUR Study drug therapy.
As part of the collaboration, both Tempus and ASCO have specific roles. Tempus sends out optimized reports for TAPUR participation to every clinician who orders a Tempus xT 596 gene assay, which is a targeted and comprehensive genomic sequencing panel that analyzes 596 clinically relevant genes as well as genes of emerging clinical relevance. Briefly, Tempus xT 596 sequences a patient’s tumor DNA and RNA together with a matched normal blood or saliva to help physicians figure out both therapies as well as clinical trials that are most suitable for their cancer patients. Tempus’ TAPUR report also includes information about genetic variations targeted by TAPUR study drugs.
Next, a TAPUR Summary is generated based on the results of the Tempus xT platform, and this allows clinical sites to rapidly identify and screen patients who may be eligible to take part in the study based on their tumor sequencing results.
Gary Palmer, Chief Medical Officer at Tempus reports that “We are pleased to lend support to clinicians across the country and the countless patients who can benefit from access to targeted therapies made available through this unique precision medicine trial.” He adds that, “One of the goals of Tempus is to gather as much information as possible regarding efficacy of targeted therapies in specific clinical situations and we are pleased to offer this report to support the goals of the TAPUR study.”
According to Richard L. Schilsky, MD, FACP, FASCO, ASCO Chief Medical Officer and principal investigator of the TAPUR Study, “The TAPUR Study enrolls patients with advanced cancer who are not responding to standard treatment and who have genomic alterations in their tumors that can be targeted with a TAPUR Study drug.” He also adds that the optimized Tempus report provides vital information to TAPUR clinical sites so that they can rapidly determine who is eligible to participate.
To learn more about the TAPUR Study, please visit https://www.tapur.org/
The American Society of Clinical Oncology, Inc. (ASCO®) is the global leading organization of its kind. It was founded in 1964 and has been committed to making a profound impact in cancer care ever since. Representing nearly 45,000 oncology professionals who care for people living with cancer, ASCO’s goal is to create a world where cancer can be prevented or cured by focusing on research, education, and promotion of the highest-quality patient care. Please visit www.ASCO.org to learn more.